Research We Fund
For 30 years, the Glaucoma Research Foundation has funded innovative clinical, epidemiological, and laboratory research. We will continue to lead the way in research until a cure is found.
We support promising ideas that the federal government's National Institutes of Health and large drug companies may pass over as being too "new and untested."
Very often, the first-stage funding we provide results in the evidence mainstream funding sources require. This can lead to additional grants for promising projects and important advances in understanding and treating glaucoma.
Read about our strategic goals
Catalyst For a Cure »
In order to accelerate research leading to a cure for glaucoma, we have launched a consortium of four talented young scientists working in universities around the country. This outstanding group uses recent breakthroughs in neuroscience, molecular biology, genetics and immunology to identify and answer key questions about the causes and mechanisms that lead to the debilitating eye disease known as glaucoma.
Read more about the Catalyst For a Cure | Read the latest research report | Meet the researchers
Shaffer Fund for Innovative Glaucoma Research »
The Glaucoma Research Foundation provides seed money for creative projects that hold promise and explore new research territory. Our initial investments in untested researchers can lead to major government and philanthropic support.
Research Milestones »
CFC Research Featured in Major Vision Publication
David Calkins, PhD and Rebecca M. Sappington, PhD of the GRF-funded Catalyst For a Cure (CFC) research consortium published recent glaucoma research findings in the publication IOVS, and have the cover article for the September 2006 edition.
Become a Catalyst Circle Member
Your generous donation of $1000 or more will support further innovation in the quest for a cure.
Catalyst For a Cure Annual Report
For the Catalyst For a Cure (CFC) consortium, the year 2007 marked a significant transition in terms of developing a further understanding of the early mechanisms involved in glaucoma and in testing interventions that target these mechanisms. continue reading »